A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
Inclusion Criteria:
Exclusion Criteria:
Prior or Current Therapies
Stamford, Connecticut 06905, United States
Ridgewood, New Jersey 07450, United States
Setagaya-ku, 158-8531, Japan
Shinjuku-ku, 160-0004, Japan
Shinjuku-ku, 160-0008, Japan
Shinjuku-ku, 169-0072, Japan
Suita-shi, 565-0853, Japan
Takatsuki-shi, 569-1192, Japan
Gangnam-gu, 06273, South Korea
Namdong-gu, 21565, South Korea
Changhua County, 50006, Taiwan
Kaohsiung Niao Sung Dist, 83301, Taiwan